Literature DB >> 21273268

A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.

Kathelijn Fischer1, Maurice E Pouw, Daniel Lewandowski, Mart P Janssen, H Marijke van den Berg, Ben A van Hout.   

Abstract

BACKGROUND: Severe hemophilia requires life-long treatment with expensive clotting factor concentrates; studies comparing effects of different therapeutic strategies over decades are very difficult to perform. A simulation model was developed to evaluate the long-term outcome of on demand, prophylactic and mixed treatment strategies for patients with severe hemophilia A. DESIGN AND METHODS: A computer model was developed based on individual patients' data from a Dutch cohort study in which intermediate dose prophylaxis was used and a French cohort study in which on demand treatment was used, and multivariate regression analyses. This model simulated individual patients' life expectancy, onset of bleeding, life-time joint bleeds, radiological outcome and concentrate use according to the different treatment strategies.
RESULTS: According to the model, life-time on demand treatment would result in an average of 1,494 joint bleeds during the hemophiliac's life, and consumption of 4.9 million IU of factor VIII concentrate. In contrast, life-time intermediate dose prophylaxis resulted in a mean of 357 joint bleeds and factor consumption of 8.3 million IU. A multiple switch strategy (between prophylactic and on demand treatment based on bleeding pattern) resulted in a mean number of 395 joint bleeds and factor consumption of 6.6 million IU. The estimated proportion of patients with Pettersson scores over 28 points was 32% for both the prophylactic and the multiple switching strategies, compared to 76% for continuous on demand treatment.
CONCLUSIONS: The present model allows evaluation of the impact of various treatment strategies on patients' joint bleeds and clotting factor consumption. It may be expanded with additional data to allow more precise estimates and include economic evaluations of treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21273268      PMCID: PMC3084921          DOI: 10.3324/haematol.2010.029868

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  28 in total

Review 1.  Confounding and indication for treatment in evaluation of drug treatment for hypertension.

Authors:  D E Grobbee; A W Hoes
Journal:  BMJ       Date:  1997-11-01

2.  Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen.

Authors:  K Fischer; J Astermark; J G van der Bom; R Ljung; E Berntorp; D E Grobbee; H M van den Berg
Journal:  Haemophilia       Date:  2002-11       Impact factor: 4.287

3.  Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome.

Authors:  K Fischer; J G van der Bom; P Molho; C Negrier; E P Mauser-Bunschoten; G Roosendaal; P De Kleijn; D E Grobbee; H M van den Berg
Journal:  Haemophilia       Date:  2002-11       Impact factor: 4.287

4.  Haemophilia prophylaxis in young patients--a long-term follow-up.

Authors:  T Löfqvist; I M Nilsson; E Berntorp; H Pettersson
Journal:  J Intern Med       Date:  1997-05       Impact factor: 8.989

5.  Prophylactic use of factor VIII: an economic evaluation.

Authors:  R L Bohn; J Avorn; R J Glynn; I Choodnovskiy; R Haschemeyer; L M Aledort
Journal:  Thromb Haemost       Date:  1998-05       Impact factor: 5.249

6.  Production of high-potency concentrates of antihemophilic globulin in a closed-bag system.

Authors:  J G Pool; A E Shannon
Journal:  N Engl J Med       Date:  1965-12-30       Impact factor: 91.245

7.  Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis.

Authors:  P S Smith; S M Teutsch; P A Shaffer; H Rolka; B Evatt
Journal:  J Pediatr       Date:  1996-09       Impact factor: 4.406

8.  The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994.

Authors:  A H Miners; C A Sabin; K H Tolley; C A Lee
Journal:  Haemophilia       Date:  1998-01       Impact factor: 4.287

9.  Radiologic evaluation of prophylaxis in severe haemophilia.

Authors:  H Pettersson; I M Nilsson; U Hedner; K Noréhn; A Ahlberg
Journal:  Acta Paediatr Scand       Date:  1981-07

10.  A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group.

Authors:  L M Aledort; R H Haschmeyer; H Pettersson
Journal:  J Intern Med       Date:  1994-10       Impact factor: 8.989

View more
  5 in total

1.  Prophylaxis for adults with haemophilia: one size does not fit all.

Authors:  Kathelijn Fischer
Journal:  Blood Transfus       Date:  2012-04       Impact factor: 3.443

Review 2.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

3.  Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study).

Authors:  Gholamreza Toogeh; Hassan Abolghasemi; Peyman Eshghi; Mohammadreza Managhchi; Mohammadreza Shaverdi-Niasari; Katayoon Karimi; Samin Roostaei; Neda Emran; Alireza Abdollahi
Journal:  Iran J Pathol       Date:  2016

4.  Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment.

Authors:  Guenka Petrova; Konstantin Tachkov; Svetla Georgieva; Maria Dimitrova
Journal:  Biotechnol Biotechnol Equip       Date:  2014-08-26       Impact factor: 1.632

5.  Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.

Authors:  Rong Chen; Dmitry Gultyaev; Johanna Lister; Rong Han; Nan Hu; Jean Malacan; Alexander Solms; Parth Vashi; Jamie O'Hara; Shanlian Hu
Journal:  BMC Med Res Methodol       Date:  2022-08-05       Impact factor: 4.612

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.